1) Building a Kinase Active-Site Peptide Library
´Ü¹éÁú µ¥ÀÌÅͺ£À̽º·Î ºÎÅÍ ²ÙÁØÇÏ°Ô ´Ü¹éÁú Ȱ¼ºÈ¿¼ÒÀÇ Sequence¿Í Ȱ¼ºÀÚ¸®°¡ ¾Ë·ÁÁø ¹Ý¸é¿¡ °ËÃâ ¹× È®ÀÎ, Á¤·®ºÐ¼®À» À§ÇÑ ¹æ¹ýÀ» ¸¸µå´Â °ÍÀº ¿©ÀüÈ÷ µµÀüÀûÀÎ ÀÏÀÌ´Ù. ÀÌ·¯ÇÑ ÆéŸÀ̵åµéÀÇ ´ë´Ù¼ö°¡ ±×µé °¢ÀÚÀÇ È°¼ºÈ¿¼Òµé¿¡ ´ëÇÏ¿© À¯ÀϹ«ÀÌÇϱ⠶§¹®¿¡ º» ½ÇÇè ¹æ¹ýÀº Ȱ¼ºÈ¿¼ÒÀÇ È°¼ºÀÚ¸® ÆéŸÀ̵åµéÀ» Á¤¼º ºÐ¼®Çϰí Á¤·® ºÐ¼®ÇÏ´Â °Í¿¡ ÁßÁ¡À» µÎ°í ÀÖ´Ù. ´õºÒ¾î, ÀÌ·¯ÇÑ ÆéŸÀ̵åµéÀº ´Ù¾çÇÑ È°¼ºÈ¿¼Ò ¿µ¿ªÀ» °¡Áø Ȱ¼ºÈ¿¼Òµé¿¡ ´ëÇÏ¿© Ȱ¼ºÀÚ¸® ¾ïÁ¦¿¡ °üÇÏ¿© Á÷Á¢ÀûÀÎ ÅëÂûÀ» ±ÔÁ¤ÇÑ´Ù.
Ȱ¼ºÈ¿¼ÒÀÇ È°¼ºÀÚ¸® ÆéŸÀ̵åµé¿¡ ´ëÇÑ ¸ñ·ÏÀ» ¸¸µé±â À§Çؼ­´Â Ȱ¼ºÀÚ¸® ÆéŸÀ̵带 ³óÈÄÈ­½Ã۱â À§ÇÑ ¹Ìó¸® ¼¼Æ÷ ¿ëÇØ¹° »ùÇõéÀ» ActivX Desthiobiotin-ATP ¶Ç´Â -ADP Probe·Î Ç¥½ÃÇÑ´Ù. Ãʱ⿡, Proteome Discoverer SoftwareÀ» »ç¿ëÇÏ¿© µ¥ÀÌÅͺ£À̽º °Ë»öÀ» À§ÇÑ ½ºÆåÆ®¶ó ¶óÀ̺귯¸® »ý¼ºÀ» À§ÇÏ¿© ÀÏ¹Ý ¸ðµå·Î TOP 10 µ¥ÀÌÅÍ È¹µæ ¹æ¹ý(Table 1)À» »ç¿ëÇÏ¿´´Ù. ÀÌ·¯ÇÑ °Ë»öÀÇ °á°úµéÀº ÆéŸÀ̵å Sequence¿Í Desthiobiotin º¯Çü ÀÚ¸® ±×¸®°í ´Ü¹éÁú Ȱ¼ºÈ¿¼ÒÀÇ ±¸¼º¿øÀ» °áÁ¤Çϴµ¥ »ç¿ëµÈ´Ù. ´õºÒ¾î, ÀÌ·¯ÇÑ ½ÇÇè¹æ¹ýÀº ÆéŸÀ̵åÀÇ Retention Times °ú Precursor ±×¸®°í Product IonÀÇ Charge States, HCD Product IonÀÇ ºÐÆ÷ µîÀ» Æ÷ÇÔÇÏ´Â ±× ´ÙÀ½ÀÇ Targeted Acquisition ¹æ¹ýµé¿¡ Áß¿äÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇß´Ù.

ÆéŸÀ̵å Sequence´Â ´Ü¹éÁúÀÇ ±â´ÉÀ» È®ÀÎÇϱâ À§ÇÏ¿© Thermo Scientific Protein Center™ SoftwareÀ» »ç¿ëÇÏ¿´´Ù. Figure 2´Â Desthiobiotin-ATP ¶Ç´Â –ADP Probe·Î Ç¥½ÃÇÑ ÆéŸÀ̵å·ÎºÎÅÍ ºÐ¼®µÈ ´Ü¹éÁúµéÀ» º¸¿©ÁØ´Ù. µÎ Probe¸¦ »ç¿ëÇÏ¿© ½Äº°µÈ ÃÑ ´Ü¹éÁúÀÇ 13%À» ´ëÇ¥ÇÏ´Â ´Ü¹éÁú Ȱ¼ºÈ¿¼Ò¿Í ¾Ë°íÀִ ǥ½ÃµÈ ATP ´Ü¹éÁúµé(°¢°¢ 77%, 83%)¿¡ ´ëÇÏ¿© µÎ ProbeµéÀ» ¸ðµÎ ³ôÀº ƯÀ̼ºÀ» º¸¿´´Ù. ºñ·Ï µÎ Probe°¡ ºñ½ÁÇÑ ¼öÀÇ È°¼ºÈ¿¼ÒµéÀ» º¸Åë Á¤µµÀÇ Áߺ¹µÈ »óÅ·Π³óÈÄÈ­½ÃÄ×À»Áö¶óµµ, Àü¿¡ º¸°íµÈ ¹Ù¿Í °°ÀÌ Æ¯Á¤ÇÑ È°¼ºÈ¿¼Ò¿¡ ´ëÇÑ °¢°¢ÀÇ ProbeµéÀÇ ¼±È£ÇÏ´Â °áÇÕÀÌ ÀÖ´Ù. Figure 3A´Â Tao1/3ÀÇ Targeted Ȱ¼ºÀÚ¸® ÆéŸÀ̵å DIKAGNILLTEPGQVKÀÇ Retention Time¿¡¼­ÀÇ HR/AM MS ½ºÆåÆ®·³À» º¸¿©ÁÖ°í ÀÖ´Ù.


Figure 2 . Proteins identified after desthiobiotin-ATP and –ADP probe labeling and enrichment categorized by protein Function using Protein Center software. The Venn diagram shows the distribution of the resulting protein kinases identified Using each probe.

º¹ÀâÇÑ ½ºÆåÆ®·³µéÀº ÀüÇüÀûÀ¸·Î Ȱ¼ºÀÚ¸® ÆéŸÀ̵åµéÀ» ³óÈÄÈ­½ÃŲ ÈÄ¿¡ ³ªÅ¸³ª°í, Multiple Charge ¶í ´Ù¾çÇÑ ÆéŸÀ̵åµéÀ» ÇÔÀ¯Çϰí ÀÖ´Ù´Â °ÍÀÌ´Ù. ¼øÂ÷ÀûÀÎ HR/AM MS¿Í MS/MS ȹµæÀ» À§ÇÑ Q ExactiveÀÇ ¼Óµµ´Â Orbitrap Mass Analyzer¿¡¼­ C-trapÀÇ À̿ ³óµµ Áõ°¡¿Í Á¶È­¸¦ ÀÌ·ç¾î +3 Precursor°¡ 14¹øÂ°·Î ¸¹ÀÌ ÀÖ´Â ÆéŸÀ̵å ÀÓ¿¡µµ ºÒ±¸Çϰí +3 Precursor¸¦ ÀÏ¹Ý ¸ðµå¿¡¼­ ¼±ÅÃÇϰí SequencingÇÒ ¼ö ÀÖ¾ú´Ù. Figure 3B´Â +3 Charge State¸¦ °®´Â DIKAGNILLTEPGQVK Precursor¿¡ ´ëÇÏ¿© ½ÇÇèÀûÀ¸·Î ÃøÁ¤µÈ IsotopicÀÇ ºÐÆ÷¿Í ÀÌ·ÐÀûÀÎ IsotopicÀÇ ºÐÆ÷ÀÇ »óÀÀÀ» º¸¿©ÁØ´Ù. °¢°¢ÀÇ IsotopicÀº ÀÌ·ÐÀûÀÎ IsotopicÀÇ Intensity ºÐÆ÷¿Í ºñ±³ÇÏ¿´À» ¶§ 5 ppm¹Ì¸¸ ±×¸®°í 15% ¹Ì¸¸ÀÇ Mass Error¸¦ °®´Â´Ù. Figure 3C´Â 25 b- ±×¸®°í y-type Fragment À̿µé°ú ´ëÁ¶ÇÑ HCD MS/MS ½ºÆåÆ®¶ó µ¥ÀÌÅͺ£À̽º °Ë»ö°á°ú¸¦ º¸¿©ÁØ´Ù.
Fragment À̿µ鿡 ´ëÇÑ Mass ErrorÀÇ Æò±Õ°ªÀº ÃøÁ¤µÈ Product Ion IntensitiesÀÇ Àüü Order of Magnitude Range¿¡ ´ëÇØ 2 ppm¹Ì¸¸À̾ú´Ù. Mass ½ºÆåÆ®·³ Àüü¿¡ °ÉÃÄ º¯ÇÔ¾ø´Â Mass Error¸¦ À¯ÁöÇÏ´Â ´É·ÂÀº ÆéŸÀÌµå ºÐ¼®ÀÇ ½Å·Ú¼ºÀ» ¸Å¿ì Áõ°¡½Ãų ¼ö Àֱ⠶§¹®¿¡ OrbitrapÀ» ÀÌ¿ëÇÑ °ËÃâ¿¡ ÀÖ¾î Ź¿ùÇÑ ÀåÁ¡À̶ó°í ÇÒ ¼ö ÀÖ´Ù.

±Ã±ØÀûÀ¸·Î, Proteome Discoverer Software·Î ºÐ¼®µÈ 126 Ȱ¼ºÈ¿¼Ò Ȱ¼ºÀÚ¸® ÆéŸÀ̵åµéÀº »ó´ëÀûÀÎ ¾çÀ» Æò°¡ÇÏ°í ¿¹Á¤µÈ ¸ñÀû¹°Áú ȹµæÀ» À§ÇÑ Inclusion List¸¦ ¸¸µé±â À§ÇØ Pinpoint Software·Î º¸³»¾îÁø´Ù(Figure 3D).


Figure 3. Processing strategy for building kinase active-site peptides spectral libraries and target lists. Example active-site peptide DIKAGNILLTEPGQVK from Tao1/3 kinase (A, B) was identified using Proteome Discoverer software from the HCD product ion spectrum (C) with Pinpoint software used to automate target-list method building (D).